Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Assets: 2014-2024

Historic Current Assets for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $86.0 million.

  • Zevra Therapeutics' Current Assets rose 126.38% to $225.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 126.38%. This contributed to the annual value of $86.0 million for FY2024, which is 1.05% down from last year.
  • Per Zevra Therapeutics' latest filing, its Current Assets stood at $86.0 million for FY2024, which was down 1.05% from $86.9 million recorded in FY2023.
  • Zevra Therapeutics' Current Assets' 5-year high stood at $115.1 million during FY2021, with a 5-year trough of $8.4 million in FY2020.
  • Over the past 3 years, Zevra Therapeutics' median Current Assets value was $86.9 million (recorded in 2023), while the average stood at $88.6 million.
  • Per our database at Business Quant, Zevra Therapeutics' Current Assets skyrocketed by 1,272.66% in 2021 and then decreased by 19.31% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Current Assets (Yearly) stood at $8.4 million in 2020, then surged by 1,272.66% to $115.1 million in 2021, then fell by 19.31% to $92.8 million in 2022, then declined by 6.35% to $86.9 million in 2023, then fell by 1.05% to $86.0 million in 2024.